Clinical trial Recruiting at 1 site Phase1; Phase2 Interventional Ages 18 and up

Imaging lung health effects of e-cigarette use

Official title: Hyperpolarized Xenon-129 MR Imaging of the Lung:E-cigarette Sub-study

Run by University of Virginia · NCT04662658 · Data updated 2026-11-12

This study is testing how e-cigarette use affects lung health in healthy young adults by using a special imaging technique to see how well their lungs work.

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment24 (estimated)
SponsorUniversity of Virginia
Academic / other
Locations1 site (Charlottesville, Virginia)
StatusRecruiting
StartedNovember 5, 2020
Main results expectedDecember 2022
Study endsDecember 2025
Registry record updatedDecember 10, 2020
Trial IDNCT04662658 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are healthy young adults aged 21-30 who have been using e-cigarettes for more than six months and have no history of lung disease.

Probably not a fit

Patients with a history of lung disease or significant medical conditions that could affect lung function will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to investigate the health effects of e-cigarettes on the lungs of healthy young adults using a novel imaging technique called hyperpolarized xenon-129 MRI. The study will assess lung function and gas exchange by quantifying regional ventilation and gas uptake in the lungs. Participants will include e-cigarette users and non-smokers, with careful monitoring of their health status and lung function. The goal is to provide insights into the potential pulmonary risks associated with e-cigarette use, which is currently poorly understood.

Why it matters

Potential benefit: If successful, this study could provide critical data on the pulmonary effects of e-cigarettes, informing public health policies and individual health decisions.

How similar studies have gone: While there have been studies on the effects of e-cigarettes, this specific approach using hyperpolarized xenon-129 MRI is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Male and female subjects 21-30 years of age
2. At baseline health with no recent illnesses or medical conditions that would preclude enrollment as assessed by the Principal Investigator
3. Ability to understand a written informed consent form and comply with the requirements of the study.
4. E-cigarette use for more than 6 months preceding the date of enrollment and less than a 5 pack year smoking history (e-cigarette users) OR less than a 5 pack year smoking history (non-smoker group).
5. No diagnosis of any lung disease (pre-bronchodilator FEV1/FVC normal on the day of screening defined by \> 95thCI of NHANES III, ATS/ERS guideline)

Exclusion Criteria:

1. History of any lung disease
2. Control (non-smoking) group: History of illegal drug use by inhalation
3. History of CNS disease including stroke and dementia, end-stage liver disease, coronary artery disease, renal failure
4. Acute infection of any kind in the previous 6 weeks
5. Pregnancy or a possibility of pregnancy
6. Anemia
7. Inability to undergo MR imaging based on the standard clinical criteria for MRI

Where it's running

  • Snyder Building 480 Ray C. Hunt Drive
    Charlottesville, Virginia, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.